Welcome to our dedicated page for Onassis Holdings news (Ticker: ONSS), a resource for investors and traders seeking the latest updates and insights on Onassis Holdings stock.
Onassis Holdings Corp (ONSS) operates at the intersection of biotechnology, wellness solutions, and innovative financing strategies. This page serves as the definitive source for verified news and official announcements related to the company’s advancements in epigenetic reprogramming, healthcare technology, and strategic investments.
Access real-time updates on earnings reports, regulatory developments, research milestones, and partnership announcements. Investors and industry observers will find curated press releases covering key operational areas including Regulation A+ financing initiatives, portfolio company expansions, and technological breakthroughs in cellular rejuvenation research.
Our news collection prioritizes accuracy and relevance, offering:
• Financial disclosures – Quarterly results and capital allocation updates
• Strategic developments – Partnerships and portfolio expansions
• Scientific advancements – Progress in epigenetic and biotech research
• Regulatory filings – SEC submissions and compliance updates
Bookmark this page for streamlined access to ONSS’s evolving narrative within the competitive biotech and wellness sectors. Check regularly for authoritative updates that matter to stakeholders.
Onassis Holding Corp (OTC: ONSS), a wellness and biotech focused holding company, has announced the launch of a Regulation A+ financing round, aiming to raise up to $75 million annually from the public. The company has retained Dalmore Group, an investment bank with over $3.6 billion in live Reg A+ offerings, to facilitate this process.
Dalmore Group, with its 16 years of experience, has on-boarded over 270 Reg A+ issuers since 2021, positioning itself as a leader in Reg A+ financing services. This partnership is expected to provide Onassis with access to Dalmore's extensive network, including marketing and PR experts, syndication partnerships, and secondary trading solutions for Reg A+ issuers.
Onassis Holdings Corp (OTC: ONSS) has partnered with SRAX (NASDAQ: SRAX) to enhance investor communication and streamline activities with potential investors and existing shareholders. SRAX's Sequire platform will provide Onassis with real-time market data, improving the overall investor experience. Eliron Yaron, Chairman of Onassis, emphasized that effective communication is crucial for the company's plans for growth in the coming year. Onassis focuses on the distribution of nutraceuticals and herbal-based medications, collaborating with top nutrition experts to innovate and ensure effective ingredients.
Onassis Holding Corp (OTC: ONSS) announced the initiation of a Regulation A+ financing round to raise up to $75 million, aimed at expanding its operations in wellness and healthcare. The company has partnered with Dalmore Group, recognized for its success in facilitating Reg A+ offerings, having onboarded over 175 issuers since 2019. Onassis is focused on distributing nutraceuticals and herbal medications, with plans for new product manufacturing. Their products include immune-boosting supplements and they are currently working on an Investigational Medicinal Product for Covid-19.
Onassis Holding Corp (OTC: ONSS) has launched sales of its Extrax CBD vape formulations developed in the UK, now available in the EU and North America. These products offer five unique mood experiences and feature broad-spectrum CBD with no stabilizers or additives, promoting high absorption. Extensive lab tests yielded positive results, leading to the opening of a dedicated CBD vape store. Each vape contains 320mg CBD and 80% total cannabinoids, with flavors like Lemon Cake and Pina Colada. Onassis aims to enhance wellness through innovative, natural extracts.
FAQ
What is the current stock price of Onassis Holdings (ONSS)?
What is the market cap of Onassis Holdings (ONSS)?
